The Brachial Plexus Injury Market is projected to reach USD 662.2 Million by 2030 at 13.8% CAGR during the forecast period 2022-2030.
The brachial plexus is a network of nerves formed by intercommunication between the ventral roots of the lower four cervical nerves and the first thoracic nerves. Plexus are responsible to pass nerve signals to all the muscles of upper extremity. Brachial plexus injury occurs when the nerves are stretched or compressed. In severe cases, the nerves may be torn away from the spinal cord. Minor brachial plexus injury may result due to sport injuries such as football. The injuries can be treated by surgical procedure that would help to restore the functions of the nerves.
Increase in number of road accidents and sport injuries, availability of treatment options and growing demand for sports medicine are major drivers for the growth of this market. Furthermore, increase in the participation of adults in high energy sports also boost the market growth. Presence of large number of market players may restrict the entry of new players.
FIGURE 1 Global Brachial Plexus Injury Market by Region, 2016 (%)
Source: World Health Organization, Centers for Disease Control and Prevention, U.S. National Library of Medicine, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation
Key Players in the Global Brachial plexus injury Market
Some of the key players in this market are Pfizer (U.S.), Abbvie Inc. (U.S.), Johnson & Johnson (U.S.), GlaxoSmithKline (U.S.), Merck Sharp & Dohme Corp (U.S.), Novartis AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Eli Lily and Company (U.S.), AstraZeneca (U.S.) and Amgen (U.S.).
Brachial Plexus Injury Market Segments
The global brachial plexus injury market is segmented on the basis of types which includes avulsion, rupture, neurapraxia, axonotemesis, neurotemesis and neuroma.
On the basis of diagnosis, the market is segmented into clinical examination, electro diagnostic studies and imaging studies. Electro diagnostic studies is segmented is sub-segmented into electromyography, Nerve Conduction Velocity (NCV), SNAP technology, and Somatosensory Evoked Potential (SSEP). Imaging studies is sub-segmented into CT, and MRI.
On the basis of treatment, the market is segmented into therapy and surgery. Therapy is segmented is sub-segmented into physical rehabilitation therapy, aquatic therapy, therapeutic taping, and aquatic therapy. Surgery is sub-segmented into nerve graft, nerve transfer and muscle transfer.
On the basis of drug, the market is segmented into Nonsteroidal anti-inflammatory drugs, Anticonvulsants, Tricyclic antidepressants and Analgesics. Nonsteroidal anti-inflammatory drugs is segmented is sub-segmented into celecoxib and naproxen. Anticonvulsants is segmented is sub-segmented into gabapentin. Tricyclic antidepressants is segmented is sub-segmented into nortriptyline and doxepin. Analgesics is segmented is sub-segmented into methadone, oxycodone and others.
On the basis of indication, the market is segmented into trauma, inflammation, contact sports, tumors, radiation treatment and others.
Source: World Health Organization, Centers for Disease Control and Prevention, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation
Europe is the second largest market that holds a noticeable share of the global brachial plexus injury market owing the availability of drugs for the treatment and an increase in the number of patients treated in emergency departments.
Asia Pacific is expected to be the fastest growing brachial plexus injury market owing to the high and ever increasing rates of traffic accidents in many of the Asia Pacific countries and the consequent demand for NSAIDs and other drugs. India is expected to be the largest market for Asia Pacific. According to the data from the Government of India reports, the total number of road accidents increased by 2.5 per cent from 4,89,400 in 2014 to 5,01,423 in 2015.
In the Middle East & Africa, the market shows steady but positive growth due to the continuous growth of healthcare diagnostics.
FIGURE 2 Research Methodology
|Market Size||USD 662.2 Million|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||By Type, Diagnosis, Treatment, Drugs and Indication|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Pfizer (U.S.), Abbvie Inc. (U.S.), Johnson & Johnson (U.S.), GlaxoSmithKline (U.S.), Merck Sharp & Dohme Corp (U.S.), Novartis AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Eli Lily and Company (U.S.), AstraZeneca (U.S.) and Amgen (U.S.)|
|Key Market Opportunities||
|Key Market Drivers||